Anorectic state of obesity medications in the United States. Are leaner times ahead?. (22nd January 2020)

• Record Type: Journal Article
• Authors: Li, Xinyi; Bello, Nicholas T.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 21:Number 2(2020)
• Page Start: 167
• Page End: 172
• Publication Date: 2020-01-22
• Subjects: Orlistat -- phentermine/topiramate -- naltrexone/bupropion -- lorcaserin -- liraglutide -- setmelanotide -- semaglutide -- dapagliflozin -- MEDI0382 -- tesofensine; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2019.1692815
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered : This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion : Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.